Investor BCLS Fund III Investments, LP
13D/G Filings

This page shows a list of all the recent 13D/G filings made by BCLS Fund III Investments, LP . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2025-08-14 13G/A DNTH / Dianthus Therapeutics, Inc. 2,689,707 2,482,250
2025-08-14 13G/A CDTX / Cidara Therapeutics, Inc. 703,080 2,500,680
2025-02-14 13G/A DNTH / Dianthus Therapeutics, Inc. 2,992,028 2,689,707
2024-10-18 13G UPB / Upstream Bio, Inc. 2,295,322
2024-07-29 13G CDTX / Cidara Therapeutics, Inc. 703,080
2024-02-02 13G DNTH / Dianthus Therapeutics, Inc. 2,992,028